<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Neurosyphilis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Neurosyphilis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Neurosyphilis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christina M Marra, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco González-Scarano, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne Marrazzo, MD, MPH, FACP, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 12, 2020.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "neurosyphilis" refers to infection of the central nervous system (CNS) by
         <em>
          Treponema pallidum
         </em>
         , subspecies
         <em>
          pallidum
         </em>
         (hereafter termed
         <em>
          T. pallidum
         </em>
         ). Neurosyphilis can occur at any time after initial infection.
        </p>
        <p>
         Early in the course of syphilis, the most common forms of neurosyphilis involve the cerebrospinal fluid, meninges, and vasculature (asymptomatic meningitis, symptomatic meningitis, and meningovascular disease). Late in disease, the most common forms involve the brain and spinal cord parenchyma (general paralysis of the insane and tabes dorsalis). Each form has characteristic clinical findings, but in some cases there is overlap between these findings.
        </p>
        <p>
         This topic will review the pathogenesis, epidemiology, clinical findings, diagnosis, and treatment of neurosyphilis. Other aspects of syphilis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">
          "Syphilis in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurosyphilis begins with invasion of the cerebrospinal fluid (CSF), a process that probably occurs shortly after acquisition of
         <em>
          T. pallidum
         </em>
         infection. The organism can be identified in the CSF from approximately one-quarter of untreated patients with early syphilis [
         <a href="#rid1">
          1,2
         </a>
         ]. Specific strains of
         <em>
          T. pallidum
         </em>
         may be more likely to cause neurosyphilis [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Unlike other bacteria that can infect the CSF, invasion of CSF with
         <em>
          T. pallidum
         </em>
         does not always result in persistent infection, as spontaneous resolution may occur in some cases without an inflammatory response. In other cases, spontaneous resolution may occur after a transient meningitis  (
         <a class="graphic graphic_figure graphicRef64295" href="/z/d/graphic/64295.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Persistent meningitis is the result of failure to clear organisms from the CSF. Patients with persistent meningitis have "asymptomatic neurosyphilis," and individuals with this form of neurosyphilis are at risk for subsequent forms of symptomatic neurosyphilis  (
         <a class="graphic graphic_figure graphicRef64295" href="/z/d/graphic/64295.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Studies performed in the early 20
         <sup>
          th
         </sup>
         century showed that the more abnormal the CSF in asymptomatic meningitis, the more likely that symptomatic neurosyphilis would develop [
         <a href="#rid5">
          5
         </a>
         ]. In the antibiotic era, the risk of developing symptomatic neurosyphilis in individuals with asymptomatic neurosyphilis, particularly after antibiotic treatment of uncomplicated syphilis, is unknown. (See
         <a class="local">
          'Spinal fluid examination'
         </a>
         below.)
        </p>
        <p>
         The mechanism of
         <em>
          T. pallidum
         </em>
         clearance from CSF is probably similar to the immune response that occurs in peripheral infection, where opsonized organisms are cleared by activated macrophages. Supporting evidence comes from a study of nonhuman primates infected with
         <em>
          T. pallidum
         </em>
         ; the number of CSF CD4+ T cells and the amount of gamma-interferon produced by CSF lymphocytes increased throughout the period of bacterial clearance, consistent with a "Th-1-type" cellular immune response [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurosyphilis was common in the pre-antibiotic era, occurring in 25 to 35 percent of patients with syphilis [
         <a href="#rid4">
          4,7
         </a>
         ]. Of these, approximately one-third had asymptomatic neurosyphilis, one-third had tabes dorsalis, and at least 10 percent had paresis. Meningovascular syphilis was seen in about 10 percent, with the remaining patients having other forms of neurosyphilis, including symptomatic meningitis and cranial nerve abnormalities.
        </p>
        <p>
         In the current era, neurosyphilis, particularly the early forms, is most frequently seen in persons with HIV. This association may simply reflect the fact that syphilis is most common in men who have sex with men, many of whom have HIV, or it may reflect a true difference in susceptibility [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">
          "Syphilis in patients with HIV", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         For persons with HIV, the risk of asymptomatic and symptomatic neurosyphilis is increased in those with lower peripheral CD4+ T cell counts, detectable plasma HIV RNA, and/or no antiretroviral therapy [
         <a href="#rid9">
          9-14
         </a>
         ].
        </p>
        <p>
         The frequency of the late forms of neurosyphilis (general paresis and tabes dorsalis) has declined in the antibiotic era, with the result that these forms, particularly tabes dorsalis, are now uncommon [
         <a href="#rid15">
          15,16
         </a>
         ]. Many experts believe that this decline is due, at least in part, to the widespread use of antibiotics for unrelated illnesses.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurosyphilis can be classified into early forms and late forms  (
         <a class="graphic graphic_figure graphicRef64295" href="/z/d/graphic/64295.html" rel="external">
          figure 1
         </a>
         ). The early forms typically affect the cerebrospinal fluid (CSF), meninges, and vasculature, while the late forms affect the brain and spinal cord parenchyma. Most of what we know about the clinical manifestations of neurosyphilis comes from observations made before the advent of penicillin [
         <a href="#rid4">
          4,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Early neurosyphilis
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Asymptomatic neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         By definition, patients with asymptomatic neurosyphilis have no symptoms or signs of central nervous system disease, although they may have evidence of concomitant primary or secondary syphilis. Asymptomatic neurosyphilis can occur within weeks to months after infection, but less commonly occurs more than two years after infection.
        </p>
        <p>
         The diagnosis is based on the identification of CSF abnormalities, including a lymphocytic pleocytosis that is typically &lt;100 cells/microL, an elevated protein concentration that is usually &lt;100 mg/dL, a reactive CSF-Venereal Disease Research Laboratory test (VDRL), or a combination of these abnormalities.
        </p>
        <p>
         In patients with suspected asymptomatic neurosyphilis who do not have HIV infection, a CSF lymphocyte count &gt;5 cells/microL or a protein concentration &gt;45 mg/dL is consistent with the diagnosis of neurosyphilis. Establishing the diagnosis of asymptomatic neurosyphilis in patients who have HIV infection with CSF pleocytosis but nonreactive CSF-VDRL is difficult because mild CSF pleocytosis and elevated protein can be due to HIV itself. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Patients with asymptomatic neurosyphilis, regardless of CSF-VDRL reactivity, should be treated for neurosyphilis to prevent progression to symptomatic disease. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Symptomatic meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most often, symptomatic meningitis occurs within the first year after infection, but it can occur years later. As with asymptomatic neurosyphilis, peripheral findings of early syphilis may coexist, particularly the rash of secondary disease.
        </p>
        <p>
         Patients with symptomatic syphilitic meningitis complain of headache, confusion, nausea and vomiting, and stiff neck. Visual acuity may be impaired if there is concomitant uveitis, vitreitis, retinitis, or optic neuropathy. Signs include cranial neuropathies, particularly of the optic, facial, or auditory nerves. (See
         <a class="local">
          'Ocular syphilis'
         </a>
         below and
         <a class="local">
          'Otosyphilis'
         </a>
         below.)
        </p>
        <p>
         Meningitis may cause hydrocephalus as well as arteritis of small-, medium-, or large-sized vessels, leading to ischemia or infarction of brain or spinal cord. (See
         <a class="local">
          'Meningovascular syphilis'
         </a>
         below.)
        </p>
        <p>
         Focal meningeal inflammation may lead to diffuse leptomeningitis or to syphilitic gummas, which are focal areas of inflammation that present as mass lesions contiguous with the leptomeninges  (
         <a class="graphic graphic_diagnosticimage graphicRef64262" href="/z/d/graphic/64262.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Meningitis, brain ischemia, or gummas may cause seizures.
        </p>
        <p>
         Syphilitic meningitis may uncommonly affect the spinal cord and cause meningomyelitis or hyperplastic pachymeningitis with polyradiculopathy. Symptoms and signs include back pain, sensory loss, incontinence, leg weakness, or muscle atrophy.
        </p>
        <p>
         The CSF abnormalities that accompany symptomatic meningitis are more severe than those seen in asymptomatic meningitis. CSF lymphocyte counts are generally between 200 to 400 cells/microL, CSF protein concentration is typically between 100 to 200 mg/dL, and CSF-VDRL is almost always reactive. Neuroimaging may show enhancement of meninges, spinal fluid, cranial nerves, or spinal roots. Cerebral gummas show focal areas of enhancement adjacent to the meninges, often with a "dural tail," and surrounding edema  (
         <a class="graphic graphic_diagnosticimage graphicRef64262" href="/z/d/graphic/64262.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Ocular syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ocular syphilis can involve almost any eye structure, but posterior uveitis and panuveitis are the most common and present with diminished visual acuity [
         <a href="#rid18">
          18
         </a>
         ]. Additional manifestations may include optic neuropathy, interstitial keratitis, anterior uveitis, and retinal vasculitis. Ocular syphilis is often, but not always, accompanied by syphilitic meningitis. Ocular syphilis may worsen when the diagnosis is not considered and patients are treated with systemic or topical corticosteroids [
         <a href="#rid19">
          19
         </a>
         ]. Reports first published in 2015 suggested that rates of ocular syphilis are increasing in the United States [
         <a href="#rid20">
          20,21
         </a>
         ]. A preliminary study found no single or predominant strain of
         <em>
          T. pallidum
         </em>
         was causing ocular syphilis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Otosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hearing loss, with or without tinnitus, should be considered as part of the neurologic symptoms or signs of neurosyphilis [
         <a href="#rid23">
          23,24
         </a>
         ]. Like ocular syphilis, hearing loss may or may not be accompanied by meningitis.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Meningovascular syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other bacterial meningitides, syphilitic meningitis can cause an infectious arteritis that may affect any vessel in the subarachnoid space surrounding the brain or spinal cord and result in thrombosis, ischemia, and infarction. This form of neurosyphilis may present as an ischemic stroke in a young person. Stroke may develop at any time from the first months to the first few years after infection, with an average interval of seven years in a series conducted in the pre-antibiotic era [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Many patients with meningovascular syphilis have prodromal symptoms, such as headache, dizziness, or personality changes, for days or weeks before the onset of ischemia or stroke. These symptoms are probably due to concomitant meningitis.
        </p>
        <p>
         The manifestations of cerebral ischemia may be acute or chronic. The neurological deficits reflect the territory of the vessel involved. The middle cerebral artery and its branches are most commonly affected. Less commonly, meningovascular disease affects the anterior spinal artery and thereby causes spinal cord infarction.
        </p>
        <p>
         The CSF abnormalities associated with meningovascular neurosyphilis are generally less severe than in those of acute meningitis, with lymphocytic pleocytosis between 10 to 100 cells/microL and protein concentration of 100 to 200 mg/dL. As with all of the early symptomatic forms of neurosyphilis, CSF-VDRL is usually but not always reactive.
        </p>
        <p>
         Angiography (performed with computed tomographic, magnetic resonance, or conventional catheter techniques) may demonstrate focal segmental arterial narrowing, focal narrowing and dilatation, or total occlusion, similar to the findings seen in other infectious or noninfectious vasculitides. Neuroimaging shows one or more areas of infarction.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Late neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         General paresis and tabes dorsalis are considered "tertiary" forms of neurosyphilis, while the early forms of neurosyphilis are not.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          General paresis
         </span>
         <span class="headingEndMark">
          —
         </span>
         General paresis (also known as general paralysis of the insane, paretic neurosyphilis, or dementia paralytica) is a progressive dementing illness. In the pre-penicillin era, general paresis resulted in death within an average of 2.5 years [
         <a href="#rid4">
          4
         </a>
         ]. General paresis usually develops 10 to 25 years after infection, but it can occur as early as two years after infection. In the first half of the 20
         <sup>
          th
         </sup>
         century, this form of neurosyphilis accounted for about 10 percent of all admissions to psychiatric hospitals.
        </p>
        <p>
         In the early stage of disease, general paresis is associated with symptoms of forgetfulness and personality change. Most affected individuals experience progression of deficits in memory and judgment leading to severe dementia. Less often, patients may develop psychiatric symptoms such as depression, mania, or psychosis. In a study of 116 patients with general paresis in China, dementia, personality change, abnormal behavior, and emotional problems were the most common findings. On initial evaluation, neurosyphilis was not suspected in 36 percent of patients, which delayed the diagnosis for 1 to 24 months [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         While the neurologic examination may be normal in some patients with general paresis, common abnormal findings include dysarthria, facial and limb hypotonia, intention tremors of the face, tongue, and hands, and reflex abnormalities. Pupillary abnormalities, including Argyll-Robertson pupils, may also be seen. However, pupillary findings are more typical of tabes dorsalis. (See
         <a class="local">
          'Tabes dorsalis'
         </a>
         below.)
        </p>
        <p>
         CSF abnormalities are the rule in paretic neurosyphilis, with elevated lymphocytes of 25 to 75 cells/microL and a protein concentration in the range of 50 to 100 mg/dL. The CSF-VDRL is reactive in virtually all patients, although rare cases with a nonreactive CSF-VDRL have been reported [
         <a href="#rid26">
          26
         </a>
         ]. Neuroimaging most commonly shows atrophy.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Tabes dorsalis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tabes dorsalis (also called locomotor ataxia) is a disease of the posterior columns of the spinal cord and of the dorsal roots. It has the longest latent period between primary infection and onset of symptoms of all forms of neurosyphilis, with the interval averaging about 20 years, but sometimes as few as three years.
        </p>
        <p>
         While tabes dorsalis was the most common form of neurosyphilis in the pre-antibiotic era, it is uncommon in the antibiotic era. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         The most frequent symptoms of tabes dorsalis are sensory ataxia and lancinating pains. The latter are characterized by sudden, brief, severe stabs of pain that may affect the limbs, back, or face and that may last for minutes or days. Less common symptoms are paresthesia and gastric crises, characterized by recurrent attacks of severe epigastric pain, nausea, and vomiting. Bladder dysfunction with urinary retention and overflow incontinence may occur early in the course of disease.
        </p>
        <p>
         Pupillary irregularities are among the most common signs in patients with tabes dorsalis, and the Argyll-Robertson pupil accounts for approximately one-half of these. An Argyll-Robertson pupil is small, does not respond to light, contracts normally to accommodation and convergence, dilates imperfectly to mydriatics, and does not dilate in response to painful stimuli. (See
         <a class="medical medical_review" href="/z/d/html/5237.html" rel="external">
          "Tonic pupil", section on 'Etiologic evaluation'
         </a>
         .)
        </p>
        <p>
         Other findings seen with tabes dorsalis include absent lower extremity reflexes, impaired vibratory and position sensation, and, less commonly, impaired touch, pain, and optic atrophy.
        </p>
        <p>
         The CSF may be completely normal in tabes dorsalis, or may show a mild lymphocytic pleocytosis with 10 to 50 cells/microL and protein concentrations of 45 to 75 mg/dL. In this form of neurosyphilis, as many as one-quarter of the CSF-VDRL tests are nonreactive.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Atypical neurosyphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some studies from the antibiotic era have reported "atypical" forms of neurosyphilis, a term that is used to describe neurosyphilis that does not fulfill the clinical criteria for one of the "classic" forms (eg, symptomatic meningitis, meningovascular syphilis, general paresis, and tabes dorsalis). As an example, a study from the early 1970s of 289 patients with reactive serum CSF fluorescent treponemal antibody absorption (FTA-ABS) tests reported that neurosyphilis was diagnosed in 241 (84 percent) based on the identification of reflex, sensory, or pupillary changes, or seizures [
         <a href="#rid27">
          27
         </a>
         ]. However, similar cases of neurosyphilis were described in the 1940s [
         <a href="#rid4">
          4
         </a>
         ]. Thus, it is likely that such "atypical" forms of neurosyphilis have always existed.
        </p>
        <p>
         That said, several modern case reports have described patients with neurosyphilis that mimicked herpes encephalitis or autoimmune encephalitis [
         <a href="#rid28">
          28,29
         </a>
         ]. These patients generally had acute onset of cognitive changes, although some patients had more slowly progressive presentations. Many had seizures. Brain MRI showed unilateral or bilateral medial temporal lobe lesions  (
         <a class="graphic graphic_diagnosticimage graphicRef103817" href="/z/d/graphic/103817.html" rel="external">
          image 2
         </a>
         ) characterized by high signal on T2 and fluid-attenuated inversion recovery (FLAIR) sequences, which resolved after treatment for neurosyphilis [
         <a href="#rid28">
          28
         </a>
         ]. In addition to mesiotemporal lobe lesions, other reports have observed MRI signal abnormalities in parietal, temporo-occipital, and thalamic regions [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
         It is difficult to categorize these cases into one of the classic clinical descriptions of neurosyphilis described above (eg, symptomatic meningitis, meningovascular syphilis, general paresis, tabes dorsalis). While patients with a more slowly progressive course could be considered to have general paresis, those with acute onset and temporal lobe imaging abnormalities present a greater challenge for classification. The features of these cases are most similar to meningovascular syphilis, except that the temporal lobe abnormalities do not respect vascular territories. Thus, it is probably best to describe them as an overlap between meningeal and parenchymal disease, rather than attribute them to one of the classic clinical forms of neurosyphilis. The fact that seizures themselves may cause reversible temporal lobe abnormalities further complicates categorization of these cases [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In his 1944 text, Stokes wrote, "The frequency of neurosyphilis in general medical practice depends to a large extent on the thoroughness of the search for signs of neuraxis involvement and the frequency with which the spinal fluid examination is employed" [
         <a href="#rid7">
          7
         </a>
         ]. This axiom remains true today. As an example, in a study from Seattle, WA, that systematically queried 68 patients with syphilis for symptoms of neurosyphilis, 8 percent had vision or hearing symptoms and approximately 4 percent had symptoms and objective confirmation of neurosyphilis [
         <a href="#rid32">
          32
         </a>
         ]. The proportion with symptoms or neurosyphilis did not differ by HIV status. In another study of cerebrospinal fluid (CSF) abnormalities in individuals with syphilis, reactive CSF-Venereal Disease Research Laboratory (VDRL), diagnostic of neurosyphilis, was significantly more common in persons with HIV who had photophobia, vision loss, gait incoordination, or moderate or greater hearing loss [
         <a href="#rid33">
          33
         </a>
         ]. No relationships between reactive CSF-VDRL and symptoms were identified in HIV-uninfected individuals.
        </p>
        <p>
         Clinical suspicion and spinal fluid examination are keys to the diagnosis of neurosyphilis  (
         <a class="graphic graphic_algorithm graphicRef57300" href="/z/d/graphic/57300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef71518" href="/z/d/graphic/71518.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lumbar puncture should be considered in the evaluation of a patient who presents with neurologic, otologic or ocular symptoms that could be caused by syphilis, but with unknown syphilis history.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lumbar puncture should be performed in the evaluation of a patient with known history of or current syphilis who presents with neurologic, otologic or ocular symptoms that could be caused by syphilis.
        </p>
        <p>
        </p>
        <p>
         Current guidelines from the Centers for Disease Control and Prevention (CDC) do not recommend lumbar puncture in patients with syphilis who do not have neurologic, otologic, or ocular symptoms, stating "CSF examination has not been associated with improved clinical outcomes in the absence of neurologic signs and symptoms" [
         <a href="#rid34">
          34
         </a>
         ]. This statement is true only because no outcomes research has been published. The issue of lumbar puncture in asymptomatic persons with HIV who have syphilis is addressed below.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Unknown syphilis history
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of an unknown syphilis history, the first step in establishing the diagnosis of neurosyphilis is confirming that the patient has been infected with
         <em>
          T. pallidum
         </em>
         , as a patient cannot have neurosyphilis without first having syphilis.
        </p>
        <p>
         Tests for syphilis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum nontreponemal tests
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Venereal disease research laboratory (VDRL)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid plasma reagin (RPR)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum treponemal tests
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluorescent treponemal antibody absorption (FTA-ABS)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          T. pallidum
         </em>
         particle agglutination assay (TPPA)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          T. pallidum
         </em>
         enzyme immunoassay (TP-EIA) and chemiluminescence immunoassay (CIA); note that TP-EIA and CIA should be confirmed with an alternative treponemal test that uses a different method
        </p>
        <p>
        </p>
        <p>
         Confirmation is straightforward when serum nontreponemal tests and treponemal tests are reactive, as they virtually always are in early neurosyphilis. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing"
         </a>
         .)
        </p>
        <p>
         Unfortunately, the nontreponemal tests (VDRL and RPR) may be nonreactive in late neurosyphilis, particularly in tabes dorsalis. When there is suspicion for late forms of neurosyphilis, serum treponemal tests should always be performed. These tests remain reactive for life in virtually all individuals regardless of previous treatment. Reactivity of these serum tests confirms that the patient has had syphilis at some time, and that he or she is at risk for neurosyphilis.
        </p>
        <p>
         Patients with nonreactive serum treponemal tests do not merit further evaluation for late neurosyphilis. (See
         <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">
          "Syphilis: Screening and diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Known syphilis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with known syphilis, a lumbar puncture with cerebrospinal fluid (CSF) examination should be performed in certain clinical situations to evaluate the possibility of symptomatic or asymptomatic neurosyphilis  (
         <a class="graphic graphic_algorithm graphicRef57300" href="/z/d/graphic/57300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef71518" href="/z/d/graphic/71518.html" rel="external">
          algorithm 2
         </a>
         ). The CDC recommendations are that CSF examination should be performed in any of the following situations [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic or ophthalmic signs or symptoms in any stage of syphilis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of active tertiary syphilis affecting other parts of the body.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment failure (including failure of serum nontreponemal tests to fall appropriately) in any stage of syphilis.
        </p>
        <p>
        </p>
        <p>
         A few caveats should be noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have ocular syphilis or otosyphilis, with or without CSF abnormalities, should receive standard neurosyphilis treatment. Ocular and otologic syphilis may not be accompanied by CSF abnormalities. The value of lumbar puncture is that if CSF abnormalities are identified, they can be followed to assess efficacy of treatment. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some experts recommend lumbar puncture for all patients with concomitant HIV infection and syphilis, regardless of stage, particularly those with serum RPR ≥1:32, peripheral blood CD4+ T cell count ≤350/microL, detectable plasma HIV RNA, or those not on antiretroviral therapy. These factors increase the odds of asymptomatic neurosyphilis three- to sixfold.
        </p>
        <p>
        </p>
        <p>
         Controversy exists regarding whether identification and treatment of asymptomatic neurosyphilis results in better patient outcomes. While data in the pre-antibiotic era suggested a benefit, no study has been performed in the modern era to address this question. We suggest lumbar puncture for persons with HIV and syphilis who have increased risk of asymptomatic neurosyphilis listed above, in agreement with European guidelines [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Spinal fluid examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         While a reactive CSF-VDRL establishes the diagnosis of neurosyphilis, a nonreactive test does not exclude the diagnosis [
         <a href="#rid36">
          36
         </a>
         ]. Furthermore, the CSF-VDRL test may be falsely positive when the CSF is visibly blood-tinged and the serum nontreponemal test titer is high [
         <a href="#rid37">
          37
         </a>
         ]. Reports of CSF-VDRL sensitivity and specificity vary depending on how neurosyphilis is defined, but the preponderance of data suggest that the test lacks sensitivity. In a monograph on neurosyphilis published during the 1940s when the disease was common, a nonreactive CSF Wassermann test, the predecessor of the CSF-VDRL, was documented in 8 to 19 percent of patients with early neurosyphilis, including meningitis and meningovasculitis, the forms that are most common today [
         <a href="#rid4">
          4
         </a>
         ]. In a modern-era study of 149 patients with laboratory and clinically defined neurosyphilis, the diagnostic sensitivity of the CSF-VDRL ranged from 67 to 72 percent [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Because the CSF-VDRL is not available in some areas of the world, the CSF-RPR is sometimes used in its place. The CSF-RPR may be nonreactive in instances where the CSF-VDRL is reactive, making it a less useful test. The CDC syphilis guidelines do not address use of the CSF-RPR for neurosyphilis diagnosis [
         <a href="#rid34">
          34
         </a>
         ]. The European guidelines state that the CSF-VDRL is preferred over the CSF-RPR [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         In contrast to the CSF-VDRL, the CSF FTA-ABS test is sensitive but not specific, particularly in asymptomatic neurosyphilis. In the setting of lymphocytic CSF pleocytosis and a nonreactive CSF-VDRL, a nonreactive CSF FTA-ABS test excludes the diagnosis of asymptomatic neurosyphilis in most instances [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Elevation of the CSF protein concentration is consistent with neurosyphilis. However, it may be less specific than CSF pleocytosis [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with suspected neurosyphilis who do not have HIV infection and who have a nonreactive CSF-VDRL, a CSF lymphocyte count &gt;5 cells/microL or a protein concentration &gt;45 mg/dL is consistent with the diagnosis of neurosyphilis  (
         <a class="graphic graphic_algorithm graphicRef57300" href="/z/d/graphic/57300.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who have HIV infection and syphilis, establishing a diagnosis of neurosyphilis is particularly difficult when the CSF-VDRL is nonreactive in the setting of a mild CSF pleocytosis. The difficulty arises because HIV itself causes mild CSF pleocytosis and mild elevation of the CSF protein concentration.
        </p>
        <p>
        </p>
        <p>
         One study found that HIV-induced CSF pleocytosis was independently and significantly associated with three factors [
         <a href="#rid42">
          42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of current antiretroviral use (OR 5.9, 95% CI 1.8-18.6)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 count &gt;200/microL (OR 23.4, 95% CI 3.1-177.3)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detectable plasma HIV RNA (OR 3.3, 95% CI 1.1-9.4)
        </p>
        <p>
        </p>
        <p>
         In persons with HIV who are taking antiretroviral agents, have CD4 counts ≤200 cells/microL, or have an undetectable plasma HIV RNA viral load, the likelihood of HIV-induced CSF pleocytosis is reduced by 70 to 96 percent [
         <a href="#rid42">
          42
         </a>
         ]. Thus, CSF pleocytosis in such patients who have syphilis is more likely to be due to neurosyphilis than to HIV.
        </p>
        <p>
         CSF concentration of the B cell chemokine CXCL13 may be useful in distinguishing between CSF pleocytosis due to syphilis and CSF pleocytosis due to HIV, but this test is not widely available [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of neurosyphilis is discussed separately and reviewed here briefly. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring", section on 'Treatment of neuro/ocular/otic syphilis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H322698763">
         <span class="h2">
          Antibiotic regimens
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurosyphillis
         </strong>
         - The standard regimens recommended by Centers for Disease Control and Prevention (CDC) guidelines for the treatment of neurosyphilis, including ocular and otosyphilis, are as follows  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aqueous crystalline
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (18 to 24 million units per day, administered as 3 to 4 million units intravenous [IV] every four hours, or 18 to 24 million units daily as a continuous infusion) for 10 to 14 days, or
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Procaine
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (2.4 million units intramuscular [IM] once daily) plus
         <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">
          probenecid
         </a>
         (500 mg orally four times a day), both for 10 to 14 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These regimens can also be used following penicillin desensitization for patients who have a serious penicillin allergy [
         <a href="#rid34">
          34
         </a>
         ]. Desensitization should be managed in consultation with a specialist (see
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Desensitization'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative treatment for patients who have a mild penicillin allergy is
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g IV or IM daily) for 10 to 14 days, with careful observation for cross-reactivity [
         <a href="#rid34">
          34,35,45
         </a>
         ]. High dose
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (200 mg orally twice a day for 21 to 28 days) also may be an effective alternative treatment [
         <a href="#rid46">
          46
         </a>
         ], but is not recommended by the CDC or European guidelines [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No controlled trials have evaluated the efficacy of the currently used forms of penicillin for neurosyphilis treatment. Thus, recommendations for treatment are based on clinical experience and on predicted penetration of penicillin into the cerebrospinal fluid (CSF) and central nervous system.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurological worsening after beginning treatment for neurosyphilis has been attributed to a Jarisch-Herxheimer reaction, and may be most common in patients treated for syphilitic dementia [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ocular syphilis and otosyphilis
         </strong>
         are treated with the same regimen as is used for neurosyphilis, regardless of the presence or absence of CSF abnormalities. Treatment with oral or topical glucocorticoids for ocular syphilis and oral glucocorticoids for otosyphilis is often used in conjunction with antibiotics.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because
         <em>
          T. pallidum
         </em>
         cannot be routinely grown in the laboratory, there is no microbiological test of cure. Thus, the success of neurosyphilis therapy is judged by resolution or stabilization of clinical abnormalities and by normalization of CSF abnormalities.
        </p>
        <p>
         Neurologic examination and lumbar puncture should be performed at three to six months after treatment and every six months thereafter until the CSF white blood cell count is normal and the CSF-Venereal Disease Research Laboratory (VDRL) is nonreactive. We suggest that failure of the CSF white blood cell count to decrease six months after therapy or failure of CSF-VDRL to decline fourfold (or to nonreactive if the initial titer is &lt;1:2) one year after therapy are indications for re-treatment. The CSF white blood cell count should decline by six months after successful treatment, and all CSF abnormalities should resolve by two years after treatment. Failure to meet these criteria should prompt retreatment. Retreatment is also indicated if any follow-up CSF sample shows an increase in CSF white blood cell count, or a fourfold increase in CSF-VDRL titer. CSF abnormalities may normalize more slowly in patients who have HIV infection compared with those who are not infected with HIV [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Normalization of serum rapid plasma reagin (RPR) titer may predict successful neurosyphilis treatment. Supporting evidence comes from a longitudinal study of 110 patients with neurosyphilis, most with HIV coinfection, who were treated for neurosyphilis [
         <a href="#rid41">
          41
         </a>
         ]. At 4, 7, and 13 months after treatment, normalization of the serum RPR test, defined as a fourfold or greater decline in RPR titer or reversion to nonreactive, predicted normalization of CSF white blood cell count and CSF-VDRL reactivity in &gt;90 percent of patients. However, the predictive value of serum RPR normalization was lower for persons with HIV who were not taking antiretroviral agents
        </p>
        <p class="headingAnchor" id="H1806510597">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Epidemiology and clinical manifestations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurosyphilis refers to infection of the central nervous system (CNS) by
         <em>
          Treponema pallidum
         </em>
         . This disorder begins with invasion of the cerebrospinal fluid (CSF), a process that probably occurs shortly after acquisition of
         <em>
          T. pallidum
         </em>
         infection. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early in the course of syphilis, the most common forms of neurosyphilis involve the CSF, meninges, and vasculature (asymptomatic meningitis, symptomatic meningitis, and meningovascular disease). Later in disease, the most common forms involve the brain and spinal cord parenchyma (general paresis and tabes dorsalis)  (
         <a class="graphic graphic_figure graphicRef64295" href="/z/d/graphic/64295.html" rel="external">
          figure 1
         </a>
         ). In the current era, early neurosyphilis is more common than late neurosyphilis, and is most frequently seen in people with HIV. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic neurosyphilis lacks symptoms or signs of CNS disease, although there may be concomitant evidence of primary or secondary syphilis. Treatment of asymptomatic neurosyphilis prevents progression to the symptomatic forms. (See
         <a class="local">
          'Asymptomatic neurosyphilis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic syphilitic meningitis is typically manifested by headache, confusion, nausea and vomiting, and stiff neck. Visual acuity may be impaired if there is concomitant uveitis, vitreitis, retinitis, or optic neuropathy. Other signs include cranial neuropathies. (See
         <a class="local">
          'Symptomatic meningitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syphilitic meningitis can cause an infectious arteritis that may affect any vessel in the subarachnoid space and result in thrombosis, ischemia, and stroke involving the brain or spinal cord. (See
         <a class="local">
          'Meningovascular syphilis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The late forms of neurosyphilis (general paresis and tabes dorsalis) are the "tertiary" forms, while the early forms of neurosyphilis are not.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General paresis is a progressive dementing illness that usually develops 10 to 25 years after infection. Symptoms of forgetfulness and personality change predominate early on, but progression leads to severe dementia. Common signs include dysarthria, facial and limb hypotonia, intention tremors of the face, tongue, and hands, and reflex abnormalities. (See
         <a class="local">
          'General paresis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tabes dorsalis, uncommon in the modern era, is a disease of the posterior columns of the spinal cord and of the dorsal roots. The latent period between primary infection and onset of symptoms averages about 20 years. The most frequent manifestations include sensory ataxia, lancinating pains, and pupillary irregularities. (See
         <a class="local">
          'Tabes dorsalis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Diagnosis summary
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical suspicion and spinal fluid examination are keys to the diagnosis of neurosyphilis. In the setting of unknown syphilis history, the first step is confirming current or previous infection with
         <em>
          T. pallidum
         </em>
         (
         <a class="graphic graphic_algorithm graphicRef57300" href="/z/d/graphic/57300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef71518" href="/z/d/graphic/71518.html" rel="external">
          algorithm 2
         </a>
         ). Serum nontreponemal tests (Venereal Disease Research Laboratory [VDRL] and rapid plasma reagin [RPR]) and serum treponemal tests (fluorescent treponemal antibody absorption [FTA-ABS],
         <em>
          T. pallidum
         </em>
         particle agglutination assay [TPPA], or
         <em>
          T. pallidum
         </em>
         enzyme immunoassay [TP-EIA] or chemiluminescence immunoassay [CIA]) are virtually always reactive in early neurosyphilis. However, the nontreponemal tests may be nonreactive in late neurosyphilis, while the treponemal tests remain reactive. Therefore, serum treponemal tests should always be performed when there is suspicion for late forms of neurosyphilis. Note that a positive TP-EIA or CIA should be confirmed with an alternative treponemal test that uses a different method. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a patient with known syphilis, we recommend lumbar puncture with CSF examination for those who have neurologic, otologic, or ocular signs or symptoms, active tertiary syphilis affecting other parts of the body, or treatment failure in any stage of syphilis. In addition, we suggest lumbar puncture for persons with HIV and syphilis who are neurologically asymptomatic but at increased risk of neurosyphilis as determined by a serum RPR titer ≥1:32, a peripheral blood CD4+ T cell count ≤350/microL, the presence of detectable plasma HIV RNA, or nontreatment with antiretroviral therapy. (See
         <a class="local">
          'Known syphilis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CSF-VDRL is specific but not sensitive for the diagnosis of neurosyphilis. In contrast, the CSF FTA-ABS test is sensitive but not specific, particularly in asymptomatic neurosyphilis. Establishing a diagnosis of neurosyphilis is difficult when the CSF-VDRL is nonreactive in patients with concurrent HIV infection and syphilis who have a mild CSF pleocytosis, because HIV itself can cause a mild CSF pleocytosis and elevation of the CSF protein concentration. (See
         <a class="local">
          'Spinal fluid examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Treatment summary
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with neurosyphilis who are not penicillin-allergic, we recommend treatment with penicillin (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). The standard regimens recommended by the Centers for Disease Control and Prevention (CDC) are listed above and shown in the table  (
         <a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">
          table 1
         </a>
         ). Patients who have a serious penicillin allergy must first undergo desensitization prior to penicillin therapy. For patients who have a mild penicillin allergy, we suggest
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g intravenous daily) for 10 to 14 days with careful observation for cross-reactivity (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with serious penicillin allergies who refuse desensitization or those who cannot be treated with penicillin and ceftriaxone, an alternative is oral
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (200 mg twice daily) for 21 to 28 days. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lumbar puncture should be performed three to six months after treatment and every six months thereafter until the CSF white blood cell count is normal and the CSF-VDRL is nonreactive. We suggest retreatment if the CSF white blood cell count does not decrease six months after therapy or the CSF-VDRL does not decline fourfold (or to nonreactive if the initial titer is &lt;1:2) one year after therapy. In addition, we suggest retreatment if there is an increase in the CSF white blood cell count, or a fourfold increase in CSF-VDRL titer, in any follow-up CSF sample. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In immunocompetent patients or patients with HIV who are taking antiretroviral agents and in whom a follow-up lumbar puncture cannot be performed, normalization of the serum RPR titer can be used as a surrogate for success of neurosyphilis treatment. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lukehart SA, Hook EW 3rd, Baker-Zander SA, et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988; 109:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra C, Sahi S, Tantalo L, et al. Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis. J Infect Dis 2010; 202:1380.
          </a>
         </li>
         <li class="breakAll">
          Merritt HH, Adams RD, Solomon HC. Neurosyphilis, Oxford University Press, New York 1946.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore JE, Hopkins H. Asymptomatic neurosyphilis. The prognosis of early and late asymptomatic neurosyphilis. JAMA 1930; 95:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Castro CD, Kuller L, et al. Mechanisms of clearance of Treponema pallidum from the CSF in a nonhuman primate model. Neurology 1998; 51:957.
          </a>
         </li>
         <li class="breakAll">
          Stokes JH, Beerman H, Ingraham NR. Modern Clinical Syphilology: Diagnosis, Treatment, Case Study, 3rd ed, WB Saunders, Philadelphia 1944.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor MM, Aynalem G, Olea LM, et al. A consequence of the syphilis epidemic among men who have sex with men (MSM): neurosyphilis in Los Angeles, 2001-2004. Sex Transm Dis 2008; 35:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poliseli R, Vidal JE, Penalva De Oliveira AC, Hernandez AV. Neurosyphilis in HIV-infected patients: clinical manifestations, serum venereal disease research laboratory titers, and associated factors to symptomatic neurosyphilis. Sex Transm Dis 2008; 35:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004; 189:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Libois A, De Wit S, Poll B, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 2007; 34:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem KG, Moore RD, Rompalo AM, et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Sahi SK, Tantalo LC, et al. Toll-like receptor polymorphisms are associated with increased neurosyphilis risk. Sex Transm Dis 2014; 41:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumaresq J, Langevin S, Gagnon S, et al. Clinical prediction and diagnosis of neurosyphilis in HIV-infected patients with early Syphilis. J Clin Microbiol 2013; 51:4060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolters EC. Neurosyphilis: a changing diagnostic problem? Eur Neurol 1987; 26:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conde-Sendín MA, Amela-Peris R, Aladro-Benito Y, Maroto AA. Current clinical spectrum of neurosyphilis in immunocompetent patients. Eur Neurol 2004; 52:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fargen KM, Alvernia JE, Lin CS, Melgar M. Cerebral syphilitic gummata: a case presentation and analysis of 156 reported cases. Neurosurgery 2009; 64:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moradi A, Salek S, Daniel E, et al. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am J Ophthalmol 2015; 159:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rescigno RJ, Glatman M, Patel SN. A complicated case of sarcoidosis. Neurosyphilis. JAMA Ophthalmol 2014; 132:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver SE, Aubin M, Atwell L, et al. Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1185.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC). Clinical advisory: ocular syphilis in the United States. www.cdc.gov/std/syphilis/clinicaladvisoryos2015.htm (Accessed on November 08, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver S, Sahi SK, Tantalo LC, et al. Molecular Typing of Treponema pallidum in Ocular Syphilis. Sex Transm Dis 2016; 43:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yimtae K, Srirompotong S, Lertsukprasert K. Otosyphilis: a review of 85 cases. Otolaryngol Head Neck Surg 2007; 136:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips JS, Gaunt A, Phillips DR. Otosyphilis: a neglected diagnosis? Otol Neurotol 2014; 35:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng D, Zhou D, Zhao Z, et al. The clinical presentation and imaging manifestation of psychosis and dementia in general paresis: a retrospective study of 116 cases. J Neuropsychiatry Clin Neurosci 2011; 23:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JW, Wilck M, Venna N. Dementia due to neurosyphilis with persistently negative CSF VDRL. Neurology 2005; 65:1838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooshmand H, Escobar MR, Kopf SW. Neurosyphilis. A study of 241 patients. JAMA 1972; 219:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karsan N, Barker R, O'Dwyer JP. Clinical reasoning: the "great imitator". Neurology 2014; 83:e188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budhram A, Silverman M, Burneo JG. Neurosyphilis mimicking autoimmune encephalitis in a 52-year-old man. CMAJ 2017; 189:E962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao Y, Huang E, Xie B, Cheng Y. Neurosyphilis presenting with psychotic symptoms and status epilepticus. Neurol Sci 2012; 33:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hicdonmez T, Utku U, Turgut N, et al. Reversible postictal MRI change mimicking structural lesion. Clin Neurol Neurosurg 2003; 105:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dombrowski JC, Pedersen R, Marra CM, et al. Prevalence Estimates of Complicated Syphilis. Sex Transm Dis 2015; 42:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis AP, Stern J, Tantalo L, et al. How Well Do Neurologic Symptoms Identify Individuals With Neurosyphilis? Clin Infect Dis 2018; 66:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol 2014; 28:1581.
          </a>
         </li>
         <li class="breakAll">
          Larsen SA, Hambie EA, Wobig GH, Kennedy EJ. Cerebrospinal fluid serologic test for syphilis: treponemal and nontreponemal tests. In: Advances in sexually transmitted diseases, Morisset R, Kurstak E (Eds), VNU Science Press, Utrecht 1986. p.157-162.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izzat NN, Bartruff JK, Glicksman JM, et al. Validity of the VDRL test on cerebrospinal fluid contaminated by blood. Br J Vener Dis 1971; 47:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Tantalo LC, Maxwell CL, et al. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex Transm Dis 2012; 39:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis 2012; 39:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004; 38:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008; 47:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Maxwell CL, Collier AC, et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Tantalo LC, Sahi SK, et al. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 2010; 37:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mothapo KM, Verbeek MM, van der Velden LB, et al. Has CXCL13 an added value in diagnosis of neurosyphilis? J Clin Microbiol 2015; 53:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000; 30:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985; 28:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Punia V, Rayi A, Sivaraju A. Stroke after Initiating IV Penicillin for Neurosyphilis: A Possible Jarisch-Herxheimer Reaction. Case Rep Neurol Med 2014; 2014:548179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis LE, Oyer R, Beckham JD, Tyler KL. Elevated CSF cytokines in the Jarisch-Herxheimer reaction of general paresis. JAMA Neurol 2013; 70:1060.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7599 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3056164" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9235493" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868271" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868271" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Asymptomatic neurosyphilis. The prognosis of early and late asymptomatic neurosyphilis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781512" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mechanisms of clearance of Treponema pallidum from the CSF in a nonhuman primate model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781512" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mechanisms of clearance of Treponema pallidum from the CSF in a nonhuman primate model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18446083" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A consequence of the syphilis epidemic among men who have sex with men (MSM): neurosyphilis in Los Angeles, 2001-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18446082" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Neurosyphilis in HIV-infected patients: clinical manifestations, serum venereal disease research laboratory titers, and associated factors to symptomatic neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14745693" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16865051" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : HIV and syphilis: when to perform a lumbar puncture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18525260" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Neurosyphilis in a clinical cohort of HIV-1-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24922103" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Toll-like receptor polymorphisms are associated with increased neurosyphilis risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24088852" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical prediction and diagnosis of neurosyphilis in HIV-infected patients with early Syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3545845" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Neurosyphilis: a changing diagnostic problem?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15237250" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Current clinical spectrum of neurosyphilis in immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19240620" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cerebral syphilitic gummata: a case presentation and analysis of 156 reported cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447116" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical features and incidence rates of ocular complications in patients with ocular syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810695" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A complicated case of sarcoidosis. Neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27811837" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27811837" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27419819" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Molecular Typing of Treponema pallidum in Ocular Syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17210336" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Otosyphilis: a review of 85 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24643028" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Otosyphilis: a neglected diagnosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21948891" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The clinical presentation and imaging manifestation of psychosis and dementia in general paresis: a retrospective study of 116 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344539" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dementia due to neurosyphilis with persistently negative CSF VDRL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5066697" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Neurosyphilis. A study of 241 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25422404" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical reasoning: the "great imitator".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739848" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Neurosyphilis mimicking autoimmune encephalitis in a 52-year-old man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21468681" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Neurosyphilis presenting with psychotic symptoms and status epilepticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12954549" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Reversible postictal MRI change mimicking structural lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26562700" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prevalence Estimates of Complicated Syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020214" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : How Well Do Neurologic Symptoms Identify Individuals With Neurosyphilis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sexually transmitted diseases treatment guidelines, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25348878" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : 2014 European guideline on the management of syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25348878" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : 2014 European guideline on the management of syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5090739" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Validity of the VDRL test on cerebrospinal fluid contaminated by blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592831" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421696" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034833" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18715154" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475004" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20393380" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25788544" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Has CXCL13 an added value in diagnosis of neurosyphilis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10722441" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3834836" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25431710" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Stroke after Initiating IV Penicillin for Neurosyphilis: A Possible Jarisch-Herxheimer Reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23732875" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Elevated CSF cytokines in the Jarisch-Herxheimer reaction of general paresis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
